BOSTON , MA — By the beginning of this year, a consensus had developed on the link between COX-2 drugs and heart disease risk: The evidence for cardiovascular side effects was strongest for Vioxx and Bextra, intermediate for Celebrex, and weak for naproxen. An overview article in the March issue of the Harvard Health Letter explains this consensus, and can serve as a base of information that readers can turn to as this story continues to unfold.
The Harvard Health Letter outlines some morals from the story of the COX-2 inhibitors, including these:
Also in this issue:
To continue reading this article, you must login
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.